Mirae Asset Venture Investment

Mirae Asset Venture Investment is the venture arm of Mirae Asset Financial Group, one of South Korea’s largest financial services firms, and operates from Seoul with significant capital flexibility across stages and sectors. The firm runs an active healthcare practice that spans biotech, medical devices, and AI in healthcare, with portfolio activity that includes companies like Neocis in robotic surgery alongside earlier-stage Korean biotech and digital therapeutics positions.

The healthcare thesis at Mirae Asset Venture Investment leans toward companies with substantial technical or scientific differentiation and meaningful global commercial potential, rather than companies indexed primarily to Korean domestic markets. Within that posture the firm has shown particular interest in surgical robotics, novel therapeutic platforms, AI-driven diagnostics, and digital therapeutics with credible regulatory pathways. The parent group’s broader financial services orientation gives the firm a clear understanding of capital markets and exit dynamics, which shapes how portfolio companies are positioned through their growth trajectories.

Check sizes typically fall in the one to five million dollar range at entry, with the firm participating from seed through Series C and follow-on capacity that scales with conviction. The geographic focus is Korea with substantial activity in companies that maintain US or international operations, including selective direct investments in non-Korean companies. The Mirae Asset brand provides credibility with Korean institutional investors, public market participants, and corporate clients, which can be valuable for portfolio companies as they build toward commercial scale and capital markets readiness.

The team is staffed with investment professionals who carry sector specializations across healthcare, technology, and consumer, supported by the broader Mirae Asset Financial Group infrastructure for diligence and portfolio support. Decision-making moves through investment committee but the firm’s scale and history make process predictable for prepared founders.

For founders, Mirae Asset Venture Investment functions as a substantial Korean institutional partner with global reach. Useful introductions tend to involve other Korean and Asian institutional investors, capital markets advisors for Korean and US listings, and corporate development conversations with strategic acquirers in pharma, medtech, and life sciences. Post-investment engagement is professional rather than founder-intensive; partners take board or observer seats where warranted and engage at major decisions but generally let management teams run their companies. Founders looking for a hands-on operating partner who will weigh in weekly will find the relationship lighter than that, but for biotech, medical device, and AI in healthcare companies that benefit from a credible Korean financial group on the cap table and a partner with global commercial perspective, Mirae Asset Venture Investment is among the more substantive options. The firm’s track record of supporting companies through international growth and capital markets transitions gives founders a reasonable expectation of what the long-term relationship can offer.